Analysis of influencing factors and preventive strategies for severe infusion reactions induced by mannatide

doi:10.5246/jcps.2022.12.081

Journal of Chinese Pharmaceutical Sciences ›› 2022, Vol. 31 ›› Issue (12): 953-958.DOI: 10.5246/jcps.2022.12.081

• Original articles • Previous Articles Next Articles

Analysis of influencing factors and preventive strategies for severe infusion reactions induced by mannatide

Zhipeng Wang^#, Hualian Zha^#, Bingqin Wen, Jianen Zhu, Li Wei^*(), Pengjiu Yu^*()

Department of Pharmacy, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China

Received:2022-10-07 Revised:2022-10-28 Accepted:2022-11-05 Online:2022-12-27 Published:2022-12-28
Contact: Li Wei, Pengjiu Yu
About author:
# Zhipeng Wang and Hualian Zha contribute equally to this manuscript.

Abstract

Abstract:

In recent years, the number of intravenous infusion reactions has been increasing with the wide application of mannatide in clinical practice. In the present study, 38 cases of mannatide-induced infusion reactions reported in a single medical center from 2017 to 2021 were retrospectively analyzed. Moreover, independent high-risk factors for severe infusion reactions were assessed by the Chi-square test. The results showed that infusion reactions caused by mannatide mainly occurred in patients over 50 years old (71.05%) and primarily occurred within 10 min of drug administration (86.84%), and patients with underlying diseases or drug allergies suffered from severe infusion reactions caused by mannatide. Therefore, the patients with advanced age, previous history of drug allergy, basic medical history, and the first use of this drug, especially within 10 min after administration, should be highly vigilant and closely monitored.

Key words: Mannatide, Infusion reactions, Allergy history, Underlying diseases

Supporting:

Zhipeng Wang, Hualian Zha, Bingqin Wen, Jianen Zhu, Li Wei, Pengjiu Yu. Analysis of influencing factors and preventive strategies for severe infusion reactions induced by mannatide[J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(12): 953-958.

Figures/Tables 3

References 15

[1]	Rombouts, M.D.; Swart, E.L.; VAN DEN Eertwegh, A.J.M.; Crul, M. Systematic review on infusion reactions to and infusion rate of monoclonal antibodies used in cancer treatment. Anticancer Res. 2020, 40, 1201–1218.
[2]	Price, M. Acute infusion-related reactions: how to recognize and intervene when these reactions occur in practice. Clin. J. Oncol. Nurs. 2021, 25, 591–594.
[3]	Fouda, G.E.; Bavbek, S. Rituximab hypersensitivity: from clinical presentation to management. Front. Pharmacol. 2020, 11, 572863.
[4]	Zhang, J.L.; Xu, C.; Wan, Y.L.; Gao, M.X. Effects of extremely low frequency magnetic field on production of mannatide by α-hemolytic Streptococcus. Bioelectromagnetics. 2016, 37, 331–337.
[5]	Wang, W.; Li, Y.Q.; Wang, Y.W.; Ren, S.T.; Li, Y.P.; Wang, B. Polyactin A is a novel and potent immunological adjuvant for peptide-based cancer vaccine. Int. Immunopharmacol. 2018, 54, 95–102.
[6]	Wang, W.W.; Wang, W.; Xu, W.J.; Liu, Q.; Zhang, Y.X.; Liu, X.H. Polyactin A and CpG enhance inactivated Pseudomonas plecoglossicida vaccine potency in large yellow croaker (Larimichthys crocea). Fish Shellfish. Immunol. 2022, 120, 133–138.
[7]	Wang, M.; Wang, B.; Fang, W.T. CD8⁺ T-cell percentage increases in diffuse large B-cell lymphoma patients receiving mannatide combined with standard regimens. J. Clin. Pharm. Ther. 2021, 46, 832–837.
[8]	Ao, J.F. Analysis of related factors in 9 cases of adverse reactions caused by mannan peptide. Anti-infective Pharmacy. 2018, 15, 830–832.
[9]	Żelechowska, P.; Brzezińska-Błaszczyk, E.; Różalska, S.; Agier, J.; Kozłowska, E. Mannan activates tissue native and IgE-sensitized mast cells to proinflammatory response and chemotaxis in TLR4-dependent manner. J. Leukoc. Biol. 2021, 109, 931–942.
[10]	Muallaoglu, S.; Disel, U.; Mertsoylu, H.; Besen, A.; Karadeniz, C.; Taner Sumbul, A.; Abali, H.; Ozyilkan, O. Acute infusion reactions to chemotherapeutic drugs: a single institute experience. J. Buon. 2013, 18, 261–267.
[11]	Jörg, L.; Yerly, D.; Helbling, A.; Pichler, W. The role of drug, dose, and the tolerance/intolerance of new drugs in multiple drug hypersensitivity syndrome. Allergy. 2020, 75, 1178–1187.
[12]	Zhao, D.H.; Chu, M.M.; Chen, J.; Wang, J.S. Meta-analysis of gemcitabine at 30 Min standard-dose infusion versus prolonged low-dose infusion for advanced non-small cell lung cancer. J. Chin. Pharm. Sci. 2017, 26, 763–770.
[13]	Bu, Y.S.; Xu, Y.G.; Cui, W.; Zhang, L.Y.; Gu, Y.F.; Sun, J.S. Analysis and research on the incidence and related factors of adverse events related to infusion in some medical institutions in Tianjin. Chin. Pharm. J. 2012, 47, 155–158.
[14]	Si, K.Y.; Wang, L.J. Report of 12 cases of adverse reactions caused by intravenous infusion of mannan peptide. Eva. Anal. Med. Chin. Hosp. 2017, 17, 116–118.
[15]	Zhang, J.W.; Yang, M.Z. Analysis on the relative factors of severe allergic reaction induced by mannatide. Chin. J. Hosp. Pharm. 2014, 34, 946–949.

Analysis of influencing factors and preventive strategies for severe infusion reactions induced by mannatide

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 3

References 15

Related Articles 0

Recommended Articles

Metrics

Comments